rIX-FP

BIOLOGICAL3 trials

Sponsors

CSL Behring

Conditions

Hemophilia B

Phase 2

A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

CompletedNCT01496274

CSL BehringHemophilia B

Start: 2012-02-29Updated: 2016-05-09

Phase 3

A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B

CompletedNCT01662531

CSL BehringHemophilia B

Start: 2013-01-31Updated: 2016-05-09

A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

CompletedNCT02053792

CSL BehringHemophilia B

Start: 2014-02-06End: 2021-06-02Updated: 2022-07-14

Related Papers

Switching and increasing prophylaxis regimen with a genetically recombinant fusion of coagulation factor IX and albumin in haemophilia B: a case report

Current Opinion in Hematology2023-07-311 citations

Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children

Thrombosis and Haemostasis2016-01-0163 citations

Pharmacokinetic Results of Two Phase III Clinical Studies of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B (PROLONG-9FP)

Blood2014-12-067 citations